Bronchiolitis obliterans syndrome: The achilles' heel of lung transplantation

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 3, 2013, Pages 336-351

  Weigt, S Samuel ^a   Derhovanessian, Ariss ^a   Wallace, W Dean ^a   Lynch, Joseph P ^a   Belperio, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bronchiolitis obliterans syndrome; chronic rejection; lung transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; AZITHROMYCIN; CYTOKINE; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

AIRWAY OBSTRUCTION; ALLOIMMUNITY; ARTICLE; AUTOIMMUNITY; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CELL TRANSPLANTATION; CYTOLYSIS; DISEASE COURSE; DYSPNEA; FATALITY; FORCED EXPIRATORY VOLUME; HEMATOPOIETIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LONG TERM SURVIVAL; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NONHUMAN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; PUVA; REPERFUSION; RETRANSPLANTATION; STOMACH FUNDOPLICATION; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE;

AIRWAY OBSTRUCTION; ANIMALS; BRONCHIOLITIS OBLITERANS; DISEASE PROGRESSION; DYSPNEA; GRAFT REJECTION; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; RISK FACTORS; SURVIVAL;

EID: 84879947532     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1348467     Document Type: Article

References (231)

1. Christie J. D., Edwards L. B., Kucheryavaya A. Y., et al. International Society of Heart and Lung Transplantation The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant: 2012; 31 10 1073 1086
2. Knoop C., Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med: 2006; 27 5 521 533
3. Vermeulen K. M., Groen H., van der Bij W., Erasmus M. E., Koëter G. H., TenVergert E. M. The effect of bronchiolitis obliterans syndrome on health related quality of life. Clin Transplant: 2004; 18 4 377 383
4. van den Berg J. W., van Enckevort P. J., TenVergert E. M., Postma D. S., van der Bij W., Koëter G. H. Bronchiolitis obliterans syndrome and additional costs of lung transplantation. Chest: 2000; 118 6 1648 1652
5. Estenne M., Maurer J. R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant: 2002; 21 3 297 310
6. Hachem R. R., Chakinala M. M., Yusen R. D., et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med: 2004; 169 4 468 472
7. Lama V. N., Murray S., Mumford J. A., et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med: 2005; 172 3 379 383
8. Stewart S., Fishbein M. C., Snell G. I., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant: 2007; 26 12 1229 1242
9. Yousem S. A., Berry G. J., Cagle P. T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant: 1996; 15 1 Pt 1 1 15
10. Saggar R., Ross D. J., Saggar R., et al. Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft. Am J Transplant: 2008; 8 9 1921 1930
11. Finlen Copeland C. A., Snyder L. D., Zaas D. W., Turbyfill W. J., Davis W. A., Palmer S. M. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med: 2010; 182 6 784 789
12. Burton C. M., Carlsen J., Mortensen J., Andersen C. B., Milman N., Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant: 2007; 26 7 681 686
13. Estenne M., Hertz M. I. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med: 2002; 166 4 440 444
14. Heng D., Sharples L. D., McNeil K., Stewart S., Wreghitt T., Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant: 1998; 17 12 1255 1263
15. Jackson C. H., Sharples L. D., McNeil K., Stewart S., Wallwork J. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant: 2002; 21 6 658 666
16. Lama V. N., Murray S., Lonigro R. J., et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med: 2007; 175 11 1192 1198
17. Verleden G., Dupont L. Obliterative bronchiolitis. In: Lynch J. P. III, Ross D. J., eds. Lung and Heart-Lung Transplantation. Lung Biology in Health and Disease. New York Taylor & Francis: 2006; 217 723 751
18. Borthwick L. A., McIlroy E. I., Gorowiec M. R., et al. Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair. Am J Transplant: 2010; 10 3 498 509
19. Borthwick L. A., Parker S. M., Brougham K. A., et al. Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax: 2009; 64 9 770 777
20. Hodge S., Holmes M., Banerjee B., et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant: 2009; 9 4 727 733
21. Iacono A., Dauber J., Keenan R., et al. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation: 1997; 64 2 263 269
22. Lu K. C., Jaramillo A., Lecha R. L., et al. Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation: 2002; 74 9 1297 1302
23. Meloni F., Vitulo P., Cascina A., et al. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant: 2004; 23 9 1053 1060
24. Moudgil A., Bagga A., Toyoda M., Nicolaidou E., Jordan S. C., Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clin Transplant: 1999; 13 2 201 207
25. Neuringer I. P., Walsh S. P., Mannon R. B., Gabriel S., Aris R. M. Enhanced T cell cytokine gene expression in mouse airway obliterative bronchiolitis. Transplantation: 2000; 69 3 399 405
26. Räisänen-Sokolowski A., Glysing-Jensen T., Russell M. E. Leukocyte-suppressing influences of interleukin (IL)-10 in cardiac allografts: insights from IL-10 knockout mice. Am J Pathol: 1998; 153 5 1491 1500
27. Keane M. P., Gomperts B. N., Weigt S., et al. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol: 2007; 178 1 511 519
28. Lama V. N., Harada H., Badri L. N., et al. Obligatory role for interleukin-13 in obstructive lesion development in airway allografts. Am J Pathol: 2006; 169 1 47 60
29. Zhai Y., Ghobrial R. M., Busuttil R. W., Kupiec-Weglinski J. W. Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol: 1999; 19 2 155 172
30. Heidt S., Segundo D. S., Chadha R., Wood K. J. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant: 2010; 15 4 456 461
31. Chanut-Delalande H., Fichard A., Bernocco S., Garrone R., Hulmes D. J., Ruggiero F. Control of heterotypic fibril formation by collagen V is determined by chain stoichiometry. J Biol Chem: 2001; 276 26 24352 24359
32. Iwata T., Chiyo M., Yoshida S., et al. Lung transplant ischemia reperfusion injury: metalloprotease inhibition down-regulates exposure of type V collagen, growth-related oncogene-induced neutrophil chemotaxis, and tumor necrosis factor-alpha expression. Transplantation: 2008; 85 3 417 426
33. Hachem R. R., Tiriveedhi V., Patterson G. A., Aloush A., Trulock E. P., Mohanakumar T. Antibodies to K-α 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant: 2012; 12 8 2164 2171
34. Haque M. A., Mizobuchi T., Yasufuku K., et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol: 2002; 169 3 1542 1549
35. Bharat A., Fields R. C., Trulock E. P., Patterson G. A., Mohanakumar T. Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol: 2006; 177 8 5631 5638
36. Fukami N., Ramachandran S., Saini D., et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol: 2009; 182 1 309 318
37. Burlingham W. J., Love R. B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest: 2007; 117 11 3498 3506
38. Vanaudenaerde B. M., De Vleeschauwer S. I., Vos R., et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant: 2008; 8 9 1911 1920
39. Nakagiri T., Inoue M., Morii E., et al. Local IL-17 production and a decrease in peripheral blood regulatory T cells in an animal model of bronchiolitis obliterans. Transplantation: 2010; 89 11 1312 1319
40. Fan L., Benson H. L., Vittal R., et al. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am J Transplant: 2011; 11 5 911 922
41. Kollins D., Stoelcker B., Hoffmann U., et al. FOXP3+ regulatory T-cells in renal allografts: correlation with long-term graft function and acute rejection. Clin Nephrol: 2011; 75 2 91 100
42. Batsford S., Dickenmann M., Dürmüller U., Hopfer H., Gudat F., Mihatsch M. Is monitoring of FOXP3 Treg cells in renal transplants during acute cellular rejection episodes useful? Clin Nephrol: 2011; 75 2 101 106
43. Iwase H., Kobayashi T., Kodera Y., et al. Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation. Transplantation: 2011; 91 2 191 198
44. Bhorade S. M., Chen H., Molinero L., et al. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation: 2010; 90 5 540 546
45. Gregson A. L., Hoji A., Palchevskiy V., et al. Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells. PLoS ONE: 2010; 5 6 e11354
46. Bröcker V., Länger F., Fellous T. G., et al. Fibroblasts of recipient origin contribute to bronchiolitis obliterans in human lung transplants. Am J Respir Crit Care Med: 2006; 173 11 1276 1282
47. Kleeberger W., Versmold A., Rothämel T., et al. Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury. Am J Pathol: 2003; 162 5 1487 1494
48. Hertz M. I., Henke C. A., Nakhleh R. E., et al. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci U S A: 1992; 89 21 10385 10389
49. Kallio E. A., Koskinen P. K., Aavik E., Buchdunger E., Lemström K. B. Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med: 1999; 160 4 1324 1332
50. Tikkanen J. M., Hollmén M., Nykänen A. I., Wood J., Koskinen P. K., Lemström K. B. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Respir Crit Care Med: 2006; 174 10 1145 1152
51. Aharinejad S., Taghavi S., Klepetko W., Abraham D. Prediction of lung-transplant rejection by hepatocyte growth factor. Lancet: 2004; 363 9420 1503 1508
52. Charpin J. M., Stern M., Grenet D., Israël-Biet D. Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis. Am J Respir Crit Care Med: 2000; 161 6 1991 1998
53. El-Gamel A., Sim E., Hasleton P., et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant: 1999; 18 9 828 837
54. Belperio J. A., Burdick M. D., Keane M. P., et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol: 2000; 165 1 461 472
55. Belperio J. A., Keane M. P., Burdick M. D., et al. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol: 2003; 171 9 4844 4852
56. Belperio J. A., Keane M. P., Burdick M. D., et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest: 2005; 115 5 1150 1162
57. Belperio J. A., Keane M. P., Burdick M. D., et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest: 2001; 108 4 547 556
58. Belperio J. A., Keane M. P., Burdick M. D., et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol: 2002; 169 2 1037 1049
59. DiGiovine B., Lynch J. P. III, Martinez F. J., et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol: 1996; 157 9 4194 4202
60. Reynaud-Gaubert M., Marin V., Thirion X., et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant: 2002; 21 7 721 730
61. Vos R., Blondeau K., Vanaudenaerde B. M., et al. Airway colonization and gastric aspiration after lung transplantation: do birds of a feather flock together? J Heart Lung Transplant: 2008; 27 8 843 849
62. Neurohr C., Huppmann P., Samweber B., et al. Munich Lung Transplant Group Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant: 2009; 28 5 468 474
63. Jiang X., Khan M. A., Tian W., et al. Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest: 2011; 121 6 2336 2349
64. Le Moine A., Goldman M., Abramowicz D. Multiple pathways to allograft rejection. Transplantation: 2002; 73 9 1373 1381
65. Chalermskulrat W., Neuringer I. P., Schmitz J. L., et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest: 2003; 123 6 1825 1831
66. Sundaresan S., Mohanakumar T., Smith M. A., et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation: 1998; 65 5 648 653
67. SivaSai K. S., Smith M. A., Poindexter N. J., et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation: 1999; 67 8 1094 1098
68. Stanford R. E., Ahmed S., Hodson M., Banner N. R., Rose M. L. A role for indirect allorecognition in lung transplant recipients with obliterative bronchiolitis. Am J Transplant: 2003; 3 6 736 742
69. Duncan S. R., Leonard C., Theodore J., et al. Oligoclonal CD4(+) T cell expansions in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med: 2002; 165 10 1439 1444
70. Bando K., Paradis I. L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg: 1995; 110 1 4 13, discussion 13-14
71. Husain A. N., Siddiqui M. T., Holmes E. W., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med: 1999; 159 3 829 833
72. Scott A. I., Sharples L. D., Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs: 2005; 65 6 761 771
73. Verleden G. M., Dupont L. J., Van Raemdonck D. E. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J: 2005; 25 2 221 224
74. Hopkins P. M., Aboyoun C. L., Chhajed P. N., et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med: 2004; 170 9 1022 1026
75. Burton C. M., Iversen M., Scheike T., Carlsen J., Andersen C. B. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation: 2008; 85 4 547 553
76. Kroshus T. J., Kshettry V. R., Savik K., John R., Hertz M. I., Bolman R. M. III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg: 1997; 114 2 195 202
77. Hachem R. R., Khalifah A. P., Chakinala M. M., et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation: 2005; 80 10 1406 1413
78. Khalifah A. P., Hachem R. R., Chakinala M. M., et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant: 2005; 5 8 2022 2030
79. Tazelaar H. D., Yousem S. A. The pathology of combined heart-lung transplantation: an autopsy study. Hum Pathol: 1988; 19 12 1403 1416
80. Girgis R. E., Tu I., Berry G. J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant: 1996; 15 12 1200 1208
81. Sharples L. D., McNeil K., Stewart S., Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant: 2002; 21 2 271 281
82. Glanville A. R., Aboyoun C. L., Havryk A., Plit M., Rainer S., Malouf M. A. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med: 2008; 177 9 1033 1040
83. Takemoto S. K., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant: 2004; 4 7 1033 1041
84. Bittner H. B., Dunitz J., Hertz M., Bolman M. R. III, Park S. J. Hyperacute rejection in single lung transplantation-case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation: 2001; 71 5 649 651
85. Choi J. K., Kearns J., Palevsky H. I., et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med: 1999; 160 3 1015 1018
86. de Jesus Peixoto Camargo J., Marcantonio Camargo S., Marcelo Schio S., Noguchi Machuca T., Adélia Perin F. Hyperacute rejection after single lung transplantation: a case report. Transplant Proc: 2008; 40 3 867 869
87. Frost A. E., Jammal C. T., Cagle P. T. Hyperacute rejection following lung transplantation. Chest: 1996; 110 2 559 562
88. Scornik J. C., Zander D. S., Baz M. A., Donnelly W. H., Staples E. D. Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry. Transplantation: 1999; 68 10 1542 1546
89. Hadjiliadis D., Chaparro C., Reinsmoen N. L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant: 2005; 24 (7, Suppl): S249 S254
90. Shah A. S., Nwakanma L., Simpkins C., Williams J., Chang D. C., Conte J. V. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg: 2008; 85 6 1919 1924
91. Yousem S. A., Martin T., Paradis I. L., Keenan R., Griffith B. P. Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts? Hum Pathol: 1994; 25 5 525 529
92. Girnita A. L., McCurry K. R., Iacono A. T., et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant: 2004; 23 10 1135 1141
93. Girnita A. L., Duquesnoy R., Yousem S. A., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant: 2005; 5 1 131 138
94. Palmer S. M., Davis R. D., Hadjiliadis D., et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation: 2002; 74 6 799 804
95. Smith M. A., Sundaresan S., Mohanakumar T., et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg: 1998; 116 5 812 820
96. Maruyama T., Jaramillo A., Narayanan K., Higuchi T., Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant: 2005; 5 9 2126 2134
97. Westall G. P., Snell G. I., McLean C., Kotsimbos T., Williams T., Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant: 2008; 27 7 722 728
98. Wallace W. D., Reed E. F., Ross D., Lassman C. R., Fishbein M. C. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant: 2005; 24 10 1565 1570
99. Yousem S. A., Zeevi A. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol: 2012; 36 7 987 992
100. DeNicola M. M., Weigt S. S., Belperio J. A., Reed E. F., Ross D. J., Wallace W. D. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant: 2013; 32 3 326 332
101. Kalache S., Dinavahi R., Pinney S., Mehrotra A., Cunningham M. W., Heeger P. S. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol: 2011; 187 2 1023 1030
102. Nath D. S., Ilias Basha H., Tiriveedhi V., et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant: 2010; 29 11 1277 1285
103. Lemy A., Andrien M., Lionet A., et al. Posttransplant major histocompatibility complex class I chain-related gene A antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients. Transplantation: 2012; 93 12 1258 1264
104. Reinsmoen N. L., Lai C. H., Heidecke H., et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation: 2010; 90 12 1473 1477
105. Utsumi K., Sawada T., Adachi E., et al. Collagen type IV in acute rejection of kidney. Transplant Proc: 2000; 32 7 1785
106. Goers T. A., Ramachandran S., Aloush A., Trulock E., Patterson G. A., Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol: 2008; 180 7 4487 4494
107. Saini D., Weber J., Ramachandran S., et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant: 2011; 30 6 624 631
108. Adachi E., Hopkinson I., Hayashi T. Basement-membrane stromal relationships: interactions between collagen fibrils and the lamina densa. Int Rev Cytol: 1997; 173 73 156
109. Yasufuku K., Heidler K. M., Woods K. A., et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation: 2002; 73 4 500 505
110. Tiriveedhi V., Angaswamy N., Brand D., et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol: 2012; 167 1 158 168
111. Gull K., Hussey P. J., Sasse R., Schneider A., Seebeck T., Sherwin T. Tubulin isotypes: generation of diversity in cells and microtubular organelles. J Cell Sci Suppl: 1986; 5 243 255
112. Takano T., Hasegawa Y., Miyauchi A., et al. Overexpression of kalpha1 tubulin mRNA in thyroid anaplastic carcinoma. Cancer Lett: 2001; 168 1 51 55
113. Villasante A., Wang D., Dobner P., Dolph P., Lewis S. A., Cowan N. J. Six mouse alpha-tubulin mRNAs encode five distinct isotypes: testis-specific expression of two sister genes. Mol Cell Biol: 1986; 6 7 2409 2419
114. Murphy D. B. Functions of tubulin isoforms. Curr Opin Cell Biol: 1991; 3 1 43 51
115. Wang N., Yan K., Rasenick M. M. Tubulin binds specifically to the signal-transducing proteins, Gs alpha and Gi alpha 1. J Biol Chem: 1990; 265 3 1239 1242
116. Bharat A., Saini D., Steward N., et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg: 2010; 90 4 1094 1101
117. Andrade C. F., Waddell T. K., Keshavjee S., Liu M. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant: 2005; 5 5 969 975
118. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant: 2006; 6 10 2282 2291
119. Porrett P. M., Yuan X., LaRosa D. F., et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol: 2008; 181 3 1692 1699
120. Garantziotis S., Palmer S. M., Snyder L. D., et al. Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide. Transplantation: 2007; 84 8 1012 1019
121. Palmer S. M., Burch L. H., Trindade A. J., et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med: 2005; 171 7 780 785
122. Kastelijn E. A., van Moorsel C. H., Rijkers G. T., et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant: 2010; 29 6 665 671
123. Palmer S. M., Klimecki W., Yu L., et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant: 2007; 7 3 693 699
124. Carroll K. E., Dean M. M., Heatley S. L., et al. High levels of mannose-binding lectin are associated with poor outcomes after lung transplantation. Transplantation: 2011; 91 9 1044 1049
125. Hodge S., Dean M., Hodge G., Holmes M., Reynolds P. N. Decreased efferocytosis and mannose binding lectin in the airway in bronchiolitis obliterans syndrome. J Heart Lung Transplant: 2011; 30 5 589 595
126. Budd S. J., Aris R. M., Medaiyese A. A., Tilley S. L., Neuringer I. P. Increased plasma mannose binding lectin levels are associated with bronchiolitis obliterans after lung transplantation. Respir Res: 2012; 13 56
127. Christie J. D., Carby M., Bag R., Corris P., Hertz M., Weill D. ISHLT Working Group on Primary Lung Graft Dysfunction Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant: 2005; 24 10 1454 1459
128. Andrade C. F., Kaneda H., Der S., et al. Toll-like receptor and cytokine gene expression in the early phase of human lung transplantation. J Heart Lung Transplant: 2006; 25 11 1317 1323
129. Sugimoto S., Lin X., Okazaki M., et al. Monocyte differentiation is controlled by MyD88 after mouse orthotopic lung transplantation. Transplant Proc: 2009; 41 1 388 390
130. Kaczorowski D. J., Tsung A., Billiar T. R. Innate immune mechanisms in ischemia/reperfusion. Front Biosci (Elite Ed): 2009; 1 91 98
131. Moreno I., Vicente R., Ramos F., Vicente J. L., Barberá M. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc: 2007; 39 7 2425 2426
132. Serrick C., Adoumie R., Giaid A., Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation: 1994; 58 11 1158 1162
133. Karakurum M., Shreeniwas R., Chen J., et al. Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest: 1994; 93 4 1564 1570
134. Belperio J. A., Keane M. P., Burdick M. D., et al. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. J Immunol: 2005; 175 10 6931 6939
135. Shah R. J., Diamond J. M., Lederer D. J., et al. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. Transl Res: 2012; 160 6 435 442
136. Waddell T. K., Gorczynski R. M., DeCampos K. N., Patterson G. A., Slutsky A. S. Major histocompatibility complex expression and lung ischemia-reperfusion in rats. Ann Thorac Surg: 1996; 62 3 866 872
137. Bharat A., Narayanan K., Street T., et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation: 2007; 83 2 150 158
138. Prekker M. E., Nath D. S., Walker A. R., et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant: 2006; 25 4 371 378
139. Christie J. D., Kotloff R. M., Ahya V. N., et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med: 2005; 171 11 1312 1316
140. Daud S. A., Yusen R. D., Meyers B. F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med: 2007; 175 5 507 513
141. Whitson B. A., Prekker M. E., Herrington C. S., et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant: 2007; 26 10 1004 1011
142. Diamond J. M., Lederer D. J., Kawut S. M., et al. Lung Transplant Outcomes Group Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant: 2011; 11 11 2517 2522
143. Diamond J. M., Meyer N. J., Feng R., et al. Lung Transplant Outcomes Group Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med: 2012; 186 6 546 552
144. Young L. R., Hadjiliadis D., Davis R. D., Palmer S. M. Lung transplantation exacerbates gastroesophageal reflux disease. Chest: 2003; 124 5 1689 1693
145. Basseri B., Conklin J. L., Pimentel M., et al. Esophageal motor dysfunction and gastroesophageal reflux are prevalent in lung transplant candidates. Ann Thorac Surg: 2010; 90 5 1630 1636
146. Li B., Hartwig M. G., Appel J. Z., et al. Chronic aspiration of gastric fluid induces the development of obliterative bronchiolitis in rat lung transplants. Am J Transplant: 2008; 8 8 1614 1621
147. D'Ovidio F., Mura M., Tsang M., et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg: 2005; 129 5 1144 1152
148. Blondeau K., Mertens V., Vanaudenaerde B. A., et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J: 2008; 31 4 707 713
149. Mertens V., Blondeau K., Van Oudenhove L., et al. Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin. Am J Transplant: 2011; 11 2 329 335
150. Shah N., Force S. D., Mitchell P. O., et al. Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts. Transplant Proc: 2010; 42 7 2702 2706
151. Murthy S. C., Nowicki E. R., Mason D. P., et al. Pretransplant gastroesophageal reflux compromises early outcomes after lung transplantation. J Thorac Cardiovasc Surg: 2011; 142 1 47 52, e3
152. Hartwig M. G., Anderson D. J., Onaitis M. W., et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg: 2011; 92 2 462 468, 468-469
153. D'Ovidio F., Mura M., Ridsdale R., et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant: 2006; 6 8 1930 1938
154. Tang T., Chang J. C., Xie A., Davis R. D., Parker W., Lin S. S. Aspiration of gastric fluid in pulmonary allografts: Effect of pH. J Surg Res: 2013; 181 1 e31 e38
155. Hoppo T., Jarido V., Pennathur A., et al. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation. Arch Surg: 2011; 146 9 1041 1047
156. Keenan R. J., Lega M. E., Dummer J. S., et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation: 1991; 51 2 433 438
157. Cerrina J., Le Roy Ladurie F., Herve P. H., et al. Role of CMV pneumonia in the development of obliterative bronchiolitis in heart-lung and double-lung transplant recipients. Transpl Int: 1992; 5 01 S242 S245
158. Paraskeva M., Bailey M., Levvey B. J., et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant: 2011; 11 10 2190 2196
159. Luckraz H., Sharples L., McNeil K., Wreghitt T., Wallwork J. Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant: 2003; 22 3 287 291
160. Keller C. A., Cagle P. T., Brown R. W., Noon G., Frost A. E. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest: 1995; 107 4 973 980
161. Reichenspurner H., Girgis R. E., Robbins R. C., et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg: 1996; 62 5 1467 1472, discussion 1472-1473
162. Weigt S. S., Elashoff R. M., Keane M. P., et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant: 2008; 8 7 1512 1522
163. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation: 2006; 81 10 1415 1420
164. Chmiel C., Speich R., Hofer M., et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis: 2008; 46 6 831 839
165. Khalifah A. P., Hachem R. R., Chakinala M. M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med: 2004; 170 2 181 187
166. Kumar D., Erdman D., Keshavjee S., et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant: 2005; 5 8 2031 2036
167. Kumar D., Husain S., Chen M. H., et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation: 2010; 89 8 1028 1033
168. Gottlieb J., Schulz T. F., Welte T., et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation: 2009; 87 10 1530 1537
169. Neurohr C., Huppmann P., Leuchte H., et al. Munich Lung Transplant Group Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant: 2005; 5 12 2982 2991
170. Kotsimbos T. C., Snell G. I., Levvey B., et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation: 2005; 79 3 269 275
171. Weigt S. S., Derhovanessian A., Liao E., et al. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant: 2012; 12 2 477 484
172. Botha P., Archer L., Anderson R. L., et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation: 2008; 85 5 771 774
173. Vos R., Vanaudenaerde B. M., Geudens N., Dupont L. J., Van Raemdonck D. E., Verleden G. M. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J: 2008; 31 5 1037 1045
174. Gottlieb J., Mattner F., Weissbrodt H., et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med: 2009; 103 5 743 749
175. Vos R., Vanaudenaerde B. M., Verleden S. E., et al. Diagnostic value of antibodies against Pseudomonas aeruginosa in bronchoalveolar lavage fluid after lung transplantation. Transplant Proc: 2010; 42 10 4415 4420
176. Weigt S. S., Elashoff R. M., Huang C., et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant: 2009; 9 8 1903 1911
177. Martinu T., Howell D. N., Davis R. D., Steele M. P., Palmer S. M. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest: 2006; 129 4 1016 1023
178. Speich R., Boehler A., Thurnheer R., Weder W. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage. Transplantation: 1997; 64 3 533 535
179. Whyte R. I., Rossi S. J., Mulligan M. S., et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg: 1997; 64 4 945 948
180. Borro J. M., Bravo C., Solé A., et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. Transplant Proc: 2007; 39 7 2416 2419
181. Cairn J., Yek T., Banner N. R., Khaghani A., Hodson M. E., Yacoub M. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant: 2003; 22 1 50 57
182. Sarahrudi K., Carretta A., Wisser W., et al. The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int: 2002; 15 1 24 28
183. Snell G. I., Esmore D. S., Williams T. J. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest: 1996; 109 4 874 878
184. Kesten S., Rajagopalan N., Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation: 1996; 61 3 427 430
185. Reams B. D., Musselwhite L. W., Zaas D. W., et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant: 2007; 7 12 2802 2808
186. Gerhardt S. G., McDyer J. F., Girgis R. E., Conte J. V., Yang S. C., Orens J. B. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med: 2003; 168 1 121 125
187. Gottlieb J., Szangolies J., Koehnlein T., Golpon H., Simon A., Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation: 2008; 85 1 36 41
188. Porhownik N. R., Batobara W., Kepron W., Unruh H. W., Bshouty Z. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J: 2008; 15 4 199 202
189. Shitrit D., Bendayan D., Gidon S., Saute M., Bakal I., Kramer M. R. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant: 2005; 24 9 1440 1443
190. Yates B., Murphy D. M., Forrest I. A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med: 2005; 172 6 772 775
191. Vanaudenaerde B. M., Meyts I., Vos R., et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J: 2008; 32 4 832 843
192. Corris P., Small T., Ryan V., et al. A Randomised Controlled Trial Of Azithromycin Therapy In Bronchiolitis Obliterans Syndrome (BOS) Post Lung Transplantation [abstract]. Am J Respir Crit Care Med: 2012; 185 A5324
193. Knobler R. Extracorporeal photochemotherapy-present and future. Vox Sang: 2000; 78 02 197 201
194. Rook A. H., Cohen J. H., Lessin S. R., Vowels B. R. Therapeutic applications of photopheresis. Dermatol Clin: 1993; 11 2 339 347
195. Barr M. L., Meiser B. M., Eisen H. J., et al. Photopheresis Transplantation Study Group Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med: 1998; 339 24 1744 1751
196. Costanzo-Nordin M. R., Hubbell E. A., O'Sullivan E. J., et al. Successful treatment of heart transplant rejection with photopheresis. Transplantation: 1992; 53 4 808 815
197. Benden C., Speich R., Hofbauer G. F., et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation: 2008; 86 11 1625 1627
198. Jaksch P., Scheed A., Keplinger M., et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant: 2012; 31 9 950 957
199. Morrell M. R., Despotis G. J., Lublin D. M., Patterson G. A., Trulock E. P., Hachem R. R. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant: 2010; 29 4 424 431
200. George J. F., Gooden C. W., Guo L., Kirklin J. K. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis. J Heart Lung Transplant: 2008; 27 6 616 622
201. Davis R. D. Jr, Lau C. L., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg: 2003; 125 3 533 542
202. Brugière O., Thabut G., Castier Y., et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest: 2003; 123 6 1832 1837
203. Kawut S. M., Lederer D. J., Keshavjee S., et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med: 2008; 177 1 114 120
204. Palmer S. M., Miralles A. P., Lawrence C. M., Gaynor J. W., Davis R. D., Tapson V. F. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest: 1999; 116 1 127 133
205. Hartwig M. G., Snyder L. D., Appel J. Z. III., et al. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant: 2008; 27 5 547 553
206. Ailawadi G., Smith P. W., Oka T., et al. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg: 2008; 135 3 594 602
207. Garrity E. R. Jr, Villanueva J., Bhorade S. M., Husain A. N., Vigneswaran W. T. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation: 2001; 71 6 773 777
208. Lischke R., Simonek J., Davidová R., et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc: 2007; 39 1 205 212
209. Brock M. V., Borja M. C., Ferber L., et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant: 2001; 20 12 1282 1290
210. McCurry K. R., Iacono A., Zeevi A., et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg: 2005; 130 2 528 537
211. Shyu S., Dew M. A., Pilewski J. M., et al. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant: 2011; 30 7 743 754
212. McNeil K., Glanville A. R., Wahlers T., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation: 2006; 81 7 998 1003
213. Keenan R. J., Konishi H., Kawai A., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg: 1995; 60 3 580 584, discussion 584-585
214. Treede H., Klepetko W., Reichenspurner H., et al. Munich and Vienna Lung Transplant Group Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant: 2001; 20 5 511 517
215. Hachem R. R., Yusen R. D., Chakinala M. M., et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant: 2007; 26 10 1012 1018
216. Treede H., Glanville A. R., Klepetko W., et al. European and Australian Investigators in Lung Transplantation Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant: 2012; 31 8 797 804
217. Levy G., Thervet E., Lake J., Uchida K. Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation: 2002; 73 (9, Suppl): S12 S18
218. Snell G. I., Valentine V. G., Vitulo P., et al. RAD B159 Study Group Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant: 2006; 6 1 169 177
219. Dutly A. E., Gaspert A., Inci I., Schneiter D., Korom S., Weder W. The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur J Cardiothorac Surg: 2003; 24 1 154 158, discussion 158
220. Scott J. P., Smyth R. L., Higenbottam T., Mullins P., Solis E., Wallwork J. Transbronchial biopsy after lung transplantation. J Thorac Cardiovasc Surg: 1991; 101 5 935 937
221. Kukafka D. S., O'Brien G. M., Furukawa S., Criner G. J. Surveillance bronchoscopy in lung transplant recipients. Chest: 1997; 111 2 377 381
222. Arcasoy S. M., Berry G., Marboe C. C., et al. Pathologic interpretation of transbronchial biopsy for acute rejection of lung allograft is highly variable. Am J Transplant: 2011; 11 2 320 328
223. Stephenson A., Flint J., English J., et al. Interpretation of transbronchial lung biopsies from lung transplant recipients: inter- and intraobserver agreement. Can Respir J: 2005; 12 2 75 77
224. Hopkins P. M., Aboyoun C. L., Chhajed P. N., et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant: 2002; 21 10 1062 1067
225. Valentine V. G., Gupta M. R., Weill D., et al. Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation. J Heart Lung Transplant: 2009; 28 1 14 20
226. Levine S. M. Transplant/Immunology Network of the American College of Chest Physicians A survey of clinical practice of lung transplantation in North America. Chest: 2004; 125 4 1224 1238
227. Sayegh M. H., Fine N. A., Smith J. L., Rennke H. G., Milford E. L., Tilney N. L. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med: 1991; 114 11 954 955
228. Scandling J. D., Busque S., Dejbakhsh-Jones S., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med: 2008; 358 4 362 368
229. Kawai T., Cosimi A. B., Spitzer T. R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med: 2008; 358 4 353 361
230. Leventhal J., Abecassis M., Miller J., et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med: 2012; 4 124 24ra28
231. Pham S. M., Rao A. S., Zeevi A., et al. Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg: 2000; 69 2 345 350